This page shows the latest PNH news and features for those working in and with pharma, biotech and healthcare.
PNH is a rare blood condition where red blood cells are destroyed and can result in blood clots and impaired bone marrow function. ... who are clinically stable after treatment with Alexion’s older PNH drug Soliris (eculizumab).
PNH is a rare and life-threatening blood disorder with often debilitating symptoms,” said John Tsai, head global drug Development and chief medical officer, Novartis. ... We are excited to continue to explore the potential of iptacopan as new
PNH is a rare blood condition, wherein red blood cells are destroyed which can result in blood clots and impaired bone marrow function. ... Ultomiris has also been found to cause fewer episodes of breakthrough haemolysis – a symptom of PNH – thereby
PNH, an autoimmune disease characterised by the destruction of red blood cells and anaemia. ... Apellis is also conducting a study of Empaveli in treatment-naïve PNH patients – meaning they have not previously received a complement inhibitor within
NICE said clinical evidence shows Ultomiris is as effective and safe as Alexion's older PNH drug Soliris. ... stable after receiving Alexion’s older PNH drug Soliris (eculizumab) for six months or more.
Swiss pharma company Novartis has received a breakthrough therapy designation (BTD) for its experimental medication iptacopan for the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH). ... standard of care anti-complement treatment, as well
More from news
Approximately 4 fully matching, plus 24 partially matching documents found.
It is a next- generation follow-on to Soliris, Alexion’s current PNH blockbuster – also a humanised monoclonal antibody – with more convenient dosing. ... Ultomiris received approval as an Orphan Drug from the FDA for adult patients with PNH in
Alexion is bracing for the patent expiry of its blockbuster Soliris (eculizumab), used to treat paroxysmal nocturnal haemoglobinuria (PNH) and myasthenia gravis, which hit revenues of around $3bn in 2018. ... The follow-up, Ultomiris ALXN1210, is a second
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Collected Group is a forward thinking healthcare communication company that supports biopharma and diagnostic companies to engage in more lasting...